Douglas J Kojetin

List of Publications by Year
in descending order

66 papers	4,537 citations	117625 34 h-index	110387 64 g-index
80 all docs	80 docs citations	80 times ranked	6533 citing authors

#	Article	IF	Citations
1	Regulation of circadian behaviour and metabolism by synthetic REV-ERB agonists. Nature, 2012, 485, 62-68.	27.8	638
2	REV-ERB and ROR nuclear receptors as drug targets. Nature Reviews Drug Discovery, 2014, 13, 197-216.	46.4	437
3	Nuclear Receptors and Their Selective Pharmacologic Modulators. Pharmacological Reviews, 2013, 65, 710-778.	16.0	207
4	DNA binding alters coactivator interaction surfaces of the intact VDRâ€“RXR complex. Nature Structural and Molecular Biology, 2011, 18, 556-563.	8.2	185
5	Identification of SR8278, a Synthetic Antagonist of the Nuclear Heme Receptor REV-ERB. ACS Chemical Biology, 2011, 6, 131-134.	3.4	152
6	An alternate binding site for PPARÎ³ ligands. Nature Communications, 2014, 5, 3571.	12.8	148
7	Ligand and Receptor Dynamics Contribute to the Mechanism of Graded PPARÎ³ Agonism. Structure, 2012, 20, 139-150.	3.3	133
8	The REV-ERBs and RORs: molecular links between circadian rhythms and lipid homeostasis. Future Medicinal Chemistry, 2011, 3, 623-638.	2.3	131
9	Characterization of the Core Mammalian Clock Component, NPAS2, as a REV-ERBÎ±/RORÎ± Target Gene. Journal of Biological Chemistry, 2010, 285, 35386-35392.	3.4	117
10	Identification of SR3335 (ML-176): A Synthetic RORÎ± Selective Inverse Agonist. ACS Chemical Biology, 2011, 6, 218-222.	3.4	114
11	Resveratrol modulates the inflammatory response via an estrogen receptor-signal integration network. ELife, 2014, 3, e02057.	6.0	113
12	Conserved sequence-specific lincRNAâ€“steroid receptor interactions drive transcriptional repression and direct cell fate. Nature Communications, 2014, 5, 5395.	12.8	103
13	Structural mechanism for signal transduction in RXR nuclear receptor heterodimers. Nature Communications, 2015, 6, 8013.	12.8	101
14	Small Molecule Modulation of Nuclear Receptor Conformational Dynamics: Implications for Function and Drug Discovery. Molecular Pharmacology, 2013, 83, 1-8.	2.3	100
15	Pharmacological repression of PPARÎ³ promotes osteogenesis. Nature Communications, 2015, 6, 7443.	12.8	99
16	PGRMC2 is an intracellular haem chaperone critical for adipocyte function. Nature, 2019, 576, 138-142.	27.8	96
17	Ebselen, a Small-Molecule Capsid Inhibitor of HIV-1 Replication. Antimicrobial Agents and Chemotherapy, 2016, 60, 2195-2208.	3.2	91
18	Cryptic glucocorticoid receptor-binding sites pervade genomic NF-ÎºB response elements. Nature Communications, 2018, 9, 1337.	12.8	90

#	Article	IF	Citations
19	REV-ERBÎ± Regulates TH17 Cell Development and Autoimmunity. Cell Reports, 2018, 25, 3733-3749.e8.	6.4	78
20	Structure, binding interface and hydrophobic transitions of Ca2+-loaded calbindin-D28K. Nature Structural and Molecular Biology, 2006, 13, 641-647.	8.2	75
21	Tethering not required: the glucocorticoid receptor binds directly to activator protein-1 recognition motifs to repress inflammatory genes. Nucleic Acids Research, 2017, 45, 8596-8608.	14.5	69
22	Anti-proliferative actions of a synthetic REV-ERBÎ±/Î² agonist in breast cancer cells. Biochemical Pharmacology, 2015, 96, 315-322.	4.4	59
23	Identification of a Binding Site for Unsaturated Fatty Acids in the Orphan Nuclear Receptor Nurr1. ACS Chemical Biology, 2016, 11, 1795-1799.	3.4	59
24	Didehydro-Cortistatin A Inhibits HIV-1 by Specifically Binding to the Unstructured Basic Region of Tat. MBio, 2019, 10, .	4.1	56
25	Regulation of p53 Stability and Apoptosis by a ROR Agonist. PLoS ONE, 2012, 7, e34921.	2.5	54
26	Ligand-binding dynamics rewire cellular signaling via estrogen receptor-Î±. Nature Chemical Biology, 2013, 9, 326-332.	8.0	53
27	Defining a conformational ensemble that directs activation of PPARÎ³. Nature Communications, 2018, 9, 1794.	12.8	53
28	Cooperative cobinding of synthetic and natural ligands to the nuclear receptor PPARÎ³. ELife, 2018, 7, .	6.0	53
29	Implications of the binding of tamoxifen to the coactivator recognition site of the estrogen receptor. Endocrine-Related Cancer, 2008, 15, 851-870.	3.1	49
30	Synergistic Regulation of Coregulator/Nuclear Receptor Interaction by Ligand and DNA. Structure, 2017, 25, 1506-1518.e4.	3.3	45
31	A molecular switch regulating transcriptional repression and activation of PPARÎ³. Nature Communications, 2020, 11, 956.	12.8	45
32	Activity-Based Profiling Reveals a Regulatory Link between Oxidative Stress and Protein Arginine Phosphorylation. Cell Chemical Biology, 2016, 23, 967-977.	5.2	42
33	Observing selected domains in multi-domain proteins via sortase-mediated ligation and NMR spectroscopy. Journal of Biomolecular NMR, 2011, 49, 3-7.	2.8	40
34	A structural mechanism for directing corepressor-selective inverse agonism of PPARÎ³. Nature Communications, 2018, 9, 4687.	12.8	38
35	Defining a Canonical Ligand-Binding Pocket in the Orphan Nuclear Receptor Nurr1. Structure, 2019, 27, 66-77.e5.	3.3	37
36	Modification of the Orthosteric PPARÎ³ Covalent Antagonist Scaffold Yields an Improved Dual-Site Allosteric Inhibitor. ACS Chemical Biology, 2017, 12, 969-978.	3.4	36

#	Article	IF	Citations
37	CAR directs T cell adaptation to bile acids in the small intestine. Nature, 2021, 593, 147-151.	27.8	36
38	Systems Structural Biology Analysis of Ligand Effects on ERÎ± Predicts Cellular Response to Environmental Estrogens and Anti-hormone Therapies. Cell Chemical Biology, 2017, 24, 35-45.	5.2	34
39	Assessment of NR4A Ligands That Directly Bind and Modulate the Orphan Nuclear Receptor Nurr1. Journal of Medicinal Chemistry, 2020, 63, 15639-15654.	6.4	34
40	Insights into the Nature of DNA Binding of AbrB-like Transcription Factors. Structure, 2008, 16, 1702-1713.	3.3	30
41	Distal substitutions drive divergent DNA specificity among paralogous transcription factors through subdivision of conformational space. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 326-331.	7.1	28
42	Structural Basis of Altered Potency and Efficacy Displayed by a Major in Vivo Metabolite of the Antidiabetic PPARÎ³ Drug Pioglitazone. Journal of Medicinal Chemistry, 2019, 62, 2008-2023.	6.4	26
43	Alternative Splicing of a Î²4Subunit Proline-Rich Motif Regulates Voltage-Dependent Gating and Toxin Block of Cav2.1 Ca2+Channels. Journal of Neuroscience, 2002, 22, 9331-9339.	3.6	25
44	Probing the Complex Binding Modes of the PPARÎ³ Partial Agonist 2-Chloro-N-(3-chloro-4-((5-chlorobenzo[d]thiazol-2-yl)thio)phenyl)-4-(trifluoromethyl)benzenesulfonamide (T2384) to Orthosteric and Allosteric Sites with NMR Spectroscopy. Journal of Medicinal Chemistry, 2016, 59, 10335-10341.	6.4	24
45	Chemical Crosslinking Mass Spectrometry Reveals the Conformational Landscape of the Activation Helix of PPARÎ³; a Model for Ligand-Dependent Antagonism. Structure, 2018, 26, 1431-1439.e6.	3.3	24
46	Synthesis and SAR of tetrahydroisoquinolines as Rev-erbÎ± agonists. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 3739-3742.	2.2	22
47	Structure of REV-ERBÎ² Ligand-binding Domain Bound to a Porphyrin Antagonist. Journal of Biological Chemistry, 2014, 289, 20054-20066.	3.4	22
48	Mechanistic insight into protein modification and sulfur mobilization activities of noncanonical E1 and associated ubiquitinâ€like proteins of Archaea. FEBS Journal, 2016, 283, 3567-3586.	4.7	21
49	Quantitative structural assessment of graded receptor agonism. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 22179-22188.	7.1	21
50	Solution Structure and Dynamics of LuxU from Vibrio harveyi, a Phosphotransferase Protein Involved in Bacterial Quorum Sensing. Journal of Molecular Biology, 2005, 347, 297-307.	4.2	20
51	Structural Analysis of Divalent Metals Binding to the Bacillus subtilis Response Regulator Spo0F: The Possibility for In Vitro Metalloregulation in the Initiation of Sporulation. BioMetals, 2005, 18, 449-466.	4.1	19
52	Structural mechanism underlying ligand binding and activation of PPARÎ³. Structure, 2021, 29, 940-950.e4.	3.3	19
53	Structural and Motional Contributions of the Bacillus subtilis ClpC N-Domain to Adaptor Protein Interactions. Journal of Molecular Biology, 2009, 387, 639-652.	4.2	18
54	Structural organization of a major neuronal G protein regulator, the RGS7-Gβ5-R7BP complex. ELife, 2018, 7, .	6.0	18

#	Article	IF	Citations
55	The Tat inhibitor didehydroâ€cortistatin A suppresses SIV replication and reactivation. FASEB Journal, 2019, 33, 8280-8293.	0.5	17
56	Small molecule tertiary amines as agonists of the nuclear hormone receptor Rev-erbÎ±. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 4413-4417.	2.2	16
57	Deconvolution of Complex 1D NMR Spectra Using Objective Model Selection. PLoS ONE, 2015, 10, e0134474.	2.5	15
58	Structural basis for heme-dependent NCoR binding to the transcriptional repressor REV-ERBÎ². Science Advances, 2021, 7, .	10.3	13
59	Chemical systems biology reveals mechanisms of glucocorticoid receptor signaling. Nature Chemical Biology, 2021, 17, 307-316.	8.0	11
60	Sub-classification of response regulators using the surface characteristics of their receiver domains. FEBS Letters, 2003, 554, 231-236.	2.8	7
61	1H, 13C and 15N chemical shift assignments for the human Pitx2 homeodomain and a R24H homeodomain mutant. Biomolecular NMR Assignments, 2011, 5, 105-107.	0.8	4
62	Classification of Response Regulators Based on Their Surface Properties. Methods in Enzymology, 2007, 422, 141-169.	1.0	2
63	NMR assignment of the N-terminal repeat domain of Bacillus subtilis ClpC. Biomolecular NMR Assignments, 2007, 1, 163-165.	0.8	2
64	Corrigendum to: Sub-classification of response regulators using the surface characteristics of their receiver domains (FEBS 27785). FEBS Letters, 2004, 560, 227-228.	2.8	1
65	1H, 13C and 15N chemical shift assignments for the human Pitx2 homeodomain in complex with a 22-base hairpin DNA. Biomolecular NMR Assignments, 2012, 6, 79-81.	0.8	0
66	Conformational Allostery in Nuclear Receptor/Coregulator Transcriptional Complexes. Biophysical Journal, 2014, 106, 686a.	0.5	0